Multicenter Multivendor Evaluation of Dose Volume Histogram Creation Consistencies for 8 Commercial Radiation Therapy Dosimetric Systems.

Autor:	Penoncello GP; Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona; Department of Radiation Oncology, University of Colorado, Aurora, Colorado., Voss MM; Division of Biomedical Statistics and Informatics, Mayo Clinic, Scottsdale, Arizona., Gao Y; Department of Radiation Oncology, Stanford University, Palo Alto, California., Sensoy L; Department of Radiation Oncology, University of Miami, Miami, Florida., Cao M; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California., Pepin MD; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota., Herchko SM; Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida., Benedict SH; Department of Radiation Oncology, University of California Davis, Sacramento, California., DeWees TA; Department of Computational and Quantitative Medicine, City of Hope, Duarte, California; Department of Radiation Oncology, City of Hope, Duarte, California. Electronic address: tdewees@coh.org., Rong Y; Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona. Electronic address: rong.yi@mayo.edu.
Jazyk:	angličtina
Zdroj:	Practical radiation oncology [Pract Radiat Oncol] 2024 May-Jun; Vol. 14 (3), pp. e236-e248. Date of Electronic Publication: 2023 Oct 31.
DOI:	10.1016/j.prro.2023.09.009
Abstrakt:	Purpose: To evaluate dose volume histogram (DVH) construction differences across 8 major commercial treatment planning systems (TPS) and dose reporting systems for clinically treated plans of various anatomic sites and target sizes. Methods and Materials: Dose files from 10 selected clinically treated plans with a hypofractionation, stereotactic radiation therapy prescription or sharp dose gradients such as head and neck plans ranging from prescription doses of 18 Gy in 1 fraction to 70 Gy in 35 fractions, each calculated at 0.25 and 0.125 cm grid size, were created and anonymized in Eclipse TPS, and exported to 7 other major TPS (Pinnacle, RayStation, and Elements) and dose reporting systems (MIM, Mobius, ProKnow, and Velocity) systems for comparison. Dose-volume constraint points of clinical importance for each plan were collected from each evaluated system (D0.03 cc [Gy], volume, and the mean dose were used for structures without specified constraints). Each reported constraint type and structure volume was normalized to the value from Eclipse for a pairwise comparison. A Wilcoxon rank-sum test was used for statistical significance and a multivariable regression model was evaluated adjusting for plan, grid size, and distance to target center. Results: For all DVH points relative to Eclipse, all systems reported median values within 1.0% difference of each other; however, they were all different from Eclipse. Considering mean values, Pinnacle, RayStation, and Elements averaged at 1.038, 1.046, and 1.024, respectively, while MIM, Mobius, ProKnow, and Velocity reported 1.026, 1.050, 1.033, and 1.022, respectively relative to Eclipse. Smaller dose grid size improved agreement between the systems marginally without statistical significance. For structure volumes relative to Eclipse, larger differences are seen across all systems with a range in median values up to 3.0% difference and mean up to 10.1% difference. Conclusions: Large variations were observed between all systems. Eclipse generally reported, at statistically significant levels, lower values than all other evaluated systems. The nonsignificant change resulting from lowering the dose grid resolution indicates that this resolution may be less important than other aspects of calculating DVH curves, such as the 3-dimensional modeling of the structure. Competing Interests: Disclosures Minsong Cao has received funding from Varian Medical Systems and ViewRay Inc in the form of a research grant and consulting fees that are not related to this work. Stanley Benedict has received stipends as editor of Medical Physics, a journal of the American Association of Physicists in Medicine, royalties from Springer International Publishing AG (Cham, Switzerland) and CRC Press, Chapman & Hall, Garland Science Taylor & France Group LLC (Oakland, CA) for book publications unrelated to this work. He is also on the board of directors for the Radiosurgery Society, and he has not received funds related to this work. Yi Rong is on the advisory board for AstraZeneca and is the deputy editor for Medical Physics, a journal of the American Association of Physicists in Medicine. (Copyright © 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu